The EULAR has proposed 6 distinct phases (A-F) of RA, characterized by the presence of genetic risk factors (phase A), environmental factors (phase B), systemic autoimmunity associated with RA (phase C), arthralgias without clinical arthritis (phase D), unclassified arthritis (phase E), and established RA (phase F).
The relationship between lung cancer and rheumatoid arthritis remains an active topic of research, as more information is needed regarding their association.
It is important to take into consideration the epidemiology of RA-associated risks when interpreting safety data of clinical trials.
Steven C. Vlad, MD, PhD, rheumatologist at Tufts Medical Center and assistant professor of medicine at Tufts University School of Medicine, discusses the benefits and challenges of using TNF-α inhibitors to treat rheumatoid arthritis.
Christine Pham, MD, chief of the Division of Rheumatology at the Washington University School of Medicine in St Louis discusses the advantages and challenges of applying nanotherapies in rheumatoid arthritis.
Recent research points to an association between the gut microbiome composition and various types of immune-mediated inflammatory arthritides.
David T. Felson, MD, MPH, and Jos Runhaar, PhD, reflect on important population-based osteoarthritis prevention strategies and knowledge gaps that still exist in this field.
Alberto V. Carli, MD, and Ashley E. Levack, MD, MAS, discuss preventive and treatment options for periprosthetic joint infections.
Experts discuss the symptoms and prevalence of neurological manifestations in Sjogren syndrome.
A better understanding of gut microbiota and metabolites produced by them may help to predict the course and heterogeneity of rheumatoid arthritis.
